Replies to post #42099 on Relief Therapeutics Holding AG (RLFTF)

[I3ryant]

From what I’ve read, there was no approval because in the Phase Clinical III trials, there was an increased risk of stroke. I wouldn’t doubt that about the Red Cross lobbying against a blood substitute.